Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Subsequent Events (Details)

v3.21.1
Subsequent Events (Details) - Subsequent Event [Member] - USD ($)
$ in Thousands
 1 Months Ended
Mar. 31, 2021
Feb. 28, 2021
Mar. 16, 2021
Subsequent Events (Details) [Line Items]      
Issued ordinary shares 5,926,830 45,000,000  
Total consideration received (in Dollars) $ 494 $ 2,250  
Subsequent event, description     Under the terms of the distribution agreement, Ewopharma paid Can-Fite $2,250 upfront and is entitled to up to an additional $40,450 payable upon the achievement of regulatory and sales milestones plus 17.5% royalties on net sales.
ADS [Member]      
Subsequent Events (Details) [Line Items]      
Exchange for exercise of ADS 197,561 1,500,000